US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead programme, IB-T101, for clear cell renal cell carcinoma (ccRCC).

CAR-Ts have already changed the treatment landscape when it comes to blood cancers, but getting a cell therapy to market for solid tumors remains tantalizingly out of reach. Now, Inceptor Bio and cell engineering tech company Avectas are taking on the challenge.

Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, recently closed a US$37m Series A financing round led by Kineticos Ventures.

Biotechnology firm Inceptor Bio has raised $37m from Series A funding round that was led by Kineticos Ventures.

Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the closing of a $37 million Series A financing led by Kineticos Ventures.